Marcus P. Kelly

1.1k total citations
19 papers, 649 citations indexed

About

Marcus P. Kelly is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Marcus P. Kelly has authored 19 papers receiving a total of 649 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 12 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Molecular Biology. Recurrent topics in Marcus P. Kelly's work include Monoclonal and Polyclonal Antibodies Research (10 papers), HER2/EGFR in Cancer Research (8 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Marcus P. Kelly is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), HER2/EGFR in Cancer Research (8 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Marcus P. Kelly collaborates with scholars based in United States, Australia and Switzerland. Marcus P. Kelly's co-authors include Andrew M. Scott, Fiona E. Smyth, Martin W. Brechbiel, Lloyd J. Old, Gerd Ritter, Achim A. Jungbluth, John S. Bomalaski, Gavin Thurston, Jessica R. Kirshner and William C. Olson and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Biochemistry.

In The Last Decade

Marcus P. Kelly

19 papers receiving 640 citations

Peers

Countries citing papers authored by Marcus P. Kelly

Since Specialization

Citations

This map shows the geographic impact of Marcus P. Kelly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcus P. Kelly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcus P. Kelly more than expected).

Fields of papers citing papers by Marcus P. Kelly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcus P. Kelly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcus P. Kelly. The network helps show where Marcus P. Kelly may publish in the future.

Co-authorship network of co-authors of Marcus P. Kelly

This figure shows the co-authorship network connecting the top 25 collaborators of Marcus P. Kelly. A scholar is included among the top collaborators of Marcus P. Kelly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcus P. Kelly. Marcus P. Kelly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Glioblastoma Cells Use an Integrin- and CD44-Mediated Motor-Clutch Mode of Migration in Brain Tissue 2024 ·Cellular and Molecular Bioengineering ·Sarah M. Anderson, Marcus P. Kelly, David J. Odde	4
2	Abstract P134: Novel EGFRvIII-selective antibody-drug conjugate REGN3124-PBD is strongly efficacious against orthotopic glioblastoma multiforme patient derived xenografts 2021 ·Molecular Cancer Therapeutics ·Marcus P. Kelly, Sosina Makonnen, Carlos Hickey, Shu Mao, Feng Zhao, Arthur Kunz, Frank J. Delfino, Thomas Nittoli, Dangshe Ma, William C. Olson, Gavin Thurston, Jessica R. Kirshner	1
3	Preclinical PET imaging with the novel human antibody ⁸⁹Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues 2021 ·Journal for ImmunoTherapy of Cancer ·Marcus P. Kelly, Sosina Makonnen, Carlos Hickey, (unknown), Jason T. Giurleo, Richard Tavaré, (unknown), (unknown), Ishita Chatterjee, Drew Dudgeon, Marc W. Retter, Dangshe Ma, William C. Olson, Gavin Thurston, Jessica R. Kirshner	30
4	Antibody drug conjugates of cleavable amino-benzoyl-maytansinoids 2020 ·Bioorganic & Medicinal Chemistry ·Thomas Nittoli, Frank J. Delfino, Marcus P. Kelly, (unknown), (unknown), Arthur Kunz, Zhaoyuan Chen, Shu Mao, Jing Shan, Elizabeth Navarro, Feng Zhao, Sosina Makonnen, Carlos Hickey, (unknown), William C. Olson, Jessica R. Kirshner, Gavin Thurston, Nicholas Papadopoulos	4
5	ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts 2018 ·Molecular Pharmaceutics ·Sarah M. Cheal, Shutian Ruan, Darren R. Veach, Valerie A. Longo, Blesida Punzalan, (unknown), Edward K. Fung, Marcus P. Kelly, Jessica R. Kirshner, Jason T. Giurleo, George K. Ehrlich, (unknown), Gavin Thurston, William C. Olson, Pat Zanzonico, Steven M. Larson, Jorge A. Carrasquillo	4
6	Abstract 3033: Immuno-PET detection of LAG-3 expressing intratumoral lymphocytes using the zirconium-89 radiolabeled fully human anti-LAG-3 antibody REGN3767 2018 ·Cancer Research ·Marcus P. Kelly, Richard Tavaré, Jason T. Giurleo, Sosina Makonnen, Carlos Hickey, (unknown), (unknown), Dangshe Ma, Jie Dai, (unknown), Jessica R. Kirshner, William C. Olson, Gavin Thurston	14
7	Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers 2017 ·Molecular Cancer Therapeutics ·Marcus P. Kelly, Carlos Hickey, Sosina Makonnen, Sandra Coetzee, (unknown), Yu Wang, Frank J. Delfino, Jing Shan, Terra Potocky, Ishita Chatterjee, Julian Andreev, Arthur Kunz, Christopher D'Souza, Jason T. Giurleo, Thomas Nittoli, Pamela A. Trail, Gavin Thurston, Jessica R. Kirshner	19
8	Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs 2017 ·Molecular Cancer Therapeutics ·Julian Andreev, (unknown), Andrés E. Perez Bay, Frank J. Delfino, Joel W. Martin, Marcus P. Kelly, Jessica R. Kirshner, Ashique Rafique, Arthur Kunz, Thomas Nittoli, Douglas MacDonald, Christopher Daly, William C. Olson, Gavin Thurston	129
9	A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy 2013 ·PubMed ·Anurag Gupta, Natko Nuber, Christoph Esslinger, Mareike Wittenbrink, Martin Treder, Alexandro Landshammer, Takuro Noguchi, Marcus P. Kelly, Sacha Gnjatic, Erika Ritter, Lotta von Boehmer, Hiroyoshi Nishikawa, Hiroshi Shiku, Lloyd J. Old, Gerd Ritter, Alexander Knuth, Maries van den Broek	17
10	Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase 2011 ·British Journal of Cancer ·Marcus P. Kelly, Achim A. Jungbluth, (unknown), John S. Bomalaski, Lloyd J. Old, Gerd Ritter	98
11	Differential and Synergistic Effects of Epidermal Growth Factor Receptor Antibodies on Unliganded ErbB Dimers and Oligomers 2011 ·Biochemistry ·Noga Kozer, Marcus P. Kelly, Suzanne G. Orchard, Antony W. Burgess, Andrew M. Scott, Andrew H. A. Clayton	13
12	Abstract 4519: Small cell lung cancers lack expression of argininosuccinate synthase (ASS) and are sensitive to arginine deprivation using arginine deiminase-PEG20 (ADI-PEG20) 2010 ·Cancer Research ·Marcus P. Kelly, Achim A. Jungbluth, Bor-Wen Wu, John S. Bomalaski, Gerd Ritter, Lloyd J. Old	1
13	Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific immunohistochemistry-based assay and FISH analysis. 2010 ·Journal of Clinical Oncology ·Victoria Rimkunas, (unknown), Marcus P. Kelly, Matthew R. Silver, (unknown), Roberto D. Polakiewicz, (unknown), Xinmin Zhou, Herbert Haack	9
14	Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity 2010 ·The Journal of Immunology ·Takemasa Tsuji, Junko Matsuzaki, Marcus P. Kelly, Venky Ramakrishna, Laura Vitale, Li-Zhen He, Tibor Keler, Kunle Odunsi, Lloyd J. Old, Gerd Ritter, Sacha Gnjatic	100
15	Tumor Targeting by a Multivalent Single-Chain Fv (scFv) Anti-Lewis Y Antibody Construct 2008 ·Cancer Biotherapy and Radiopharmaceuticals ·Marcus P. Kelly, (unknown), (unknown), Barbara Power, Fiona E. Smyth, Martin W. Brechbiel, Peter J. Hudson, Andrew M. Scott	32
16	Therapeutic efficacy of ¹⁷⁷Lu‐CHX‐A″‐DTPA‐hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy 2008 ·The Prostate ·Marcus P. Kelly, Sze Ting Lee, (unknown), Fiona E. Smyth, Ian D. Davis, Martin W. Brechbiel, Andrew M. Scott	42
17	Radioimmunotherapy with α-Particle–Emitting 213Bi-C-Functionalized trans-Cyclohexyl-Diethylenetriaminepentaacetic Acid-Humanized 3S193 Is Enhanced by Combination with Paclitaxel Chemotherapy 2007 ·Clinical Cancer Research ·Marcus P. Kelly, (unknown), (unknown), Fiona E. Smyth, Martin W. Brechbiel, Andrew M. Scott	28
18	Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. 2006 ·PubMed ·Marcus P. Kelly, (unknown), Fiona E. Smyth, Martin W. Brechbiel, Andrew M. Scott	33
19	Enhanced Efficacy of Radioimmunotherapy with 90Y-CHX-A″-DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478 2005 ·Clinical Cancer Research ·(unknown), (unknown), Marcus P. Kelly, Cathrine Hall, Angela Rigopoulos, Terrance G. Johns, Fiona E. Smyth, Martin W. Brechbiel, Edouard C. Nice, Antony W. Burgess, Andrew M. Scott	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact